The system, which has received CE Mark approval in Europe, adds to an increasingly crowded field of PFA technologies.

Atrial Fibrillation (Afib ... an incidental diagnosis is given during a hospital visit or in the event of an acute stroke. The abnormal rhythm that Afib causes, stops the heart from pumping ...

Despite promising technology and FDA clearances, Pulse Biosciences lacks a revenue stream and remains in the testing phase ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The full results of the phase III REVERSE-IT trial continue to show that ticagrelor (Brilinta)-reversing therapy bentracimab ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

Congress, Johnson & Johnson MedTech presented pivotal 12-month safety and effectiveness data from the SmartfIRE study—offering new insights into the future of atrial fibrillation (AFib) treatment. The ...